What were the main drivers of revenue growth in this quarter?

Revenue growth was primarily driven by the Pharmaceutical Products segment and International sales. The acquisition of the pharmaceutical business of BASF in the first quarter of 2001 significantly contributed to these increases, alongside general unit growth in key product areas.

What is the impact of the FDA consent decree on the company's financials?

Abbott incurred a $129 million pre-tax charge in the second quarter of 2002 related to the FDA consent decree concerning diagnostics manufacturing. The company estimates ongoing earnings per share will be negatively impacted by approximately 9 cents in 2002 and 18 cents in 2003 due to this issue.

How is Abbott managing its legal and regulatory challenges?

Abbott is involved in several legal and regulatory matters, including antitrust suits, investigations into pharmaceutical pricing, and an industry-wide investigation into its enteral nutritional business. While management acknowledges potential impacts, they believe the ultimate disposition of these matters will not materially affect the company's financial position, results of operations, or cash flows.

What is the financial impact of recent acquisitions?

In the second quarter of 2002, Abbott acquired cardiovascular stent businesses and technology, along with increasing its stake in Hokuriku Seiyaku. These acquisitions resulted in a $108 million charge for acquired in-process R&D and significant goodwill, reflecting strategic investments in growth areas.

ABT 10-Q Quarterly Report Q2 FY2002 — Revenue, Net Income, EPS

Summary

Abbott Laboratories reported strong performance for the second quarter and first six months of 2002, with net sales increasing by 5.3% and 11.0% year-over-year, respectively. Net earnings also saw significant growth, rising to $592.3 million in the quarter and $1.45 billion for the six-month period. The company's pharmaceutical and international segments were key drivers of this growth, with the recent acquisition of BASF's pharmaceutical business contributing significantly to the year-over-year increases. Despite the positive top-line and bottom-line results, investors should note a $129 million pre-tax charge recorded in the second quarter related to a U.S. Food and Drug Administration (FDA) consent decree concerning diagnostics manufacturing. This charge, along with other one-time items, impacted reported earnings per share. The company also continues to navigate several ongoing legal and regulatory investigations, although management believes their ultimate disposition will not materially affect the company's financial position.

Key Highlights

1Net sales increased by 5.3% to $4.315 billion for the second quarter of 2002 compared to the prior year period.
2Net earnings for the second quarter of 2002 were $592.3 million, a significant increase from $529.0 million in the same period of 2001.
3Diluted earnings per share (EPS) rose to $0.38 in the second quarter of 2002 from $0.34 in the prior year, showing improved profitability on a per-share basis.
4The acquisition of BASF's pharmaceutical business in Q1 2001 continues to positively impact the Pharmaceutical and International segments, showing strong sales growth.
5A one-time pre-tax charge of $129 million was recorded in Q2 2002 related to a U.S. FDA consent decree for diagnostics manufacturing, impacting reported earnings.
6Cash flow from operating activities was robust, totaling $2.08 billion for the first six months of 2002, indicating strong cash generation capabilities.
7The company announced FDA approval for Synthroid's New Drug Application (NDA) in July 2002, lifting prior distribution limits and providing a boost to this key product.

ABBOTT LABORATORIES Quarterly Report for Q2 Ended Jun 30, 2002

Summary

Key Highlights

Frequently Asked Questions